Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

NCT04332588 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT04332588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04332588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2022
Completion date
August 31, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer